Inhibitory short synthetic oligodeoxynucleotides and lupus.
B cells and antigen-presenting cells express a group of intracellular Toll-like receptors (TLRs) that recognize nucleic acids and can be accessed only when apoptotic debris or immune complexes are internalized by B-cell receptors or Fc receptors. This results in rapid cell activation and release of inflammatory mediators that perpetuate the autoantibody response. TLR-7 and TLR-9 are required to generate autoantibodies to RNA and DNA, respectively. Synthetic oligodeoxynucleotides that inhibit the activity of these intracellular TLRs attenuate systemic lupus erythematosus in mouse models and may be of therapeutic benefit in human systemic lupus erythematosus.
Liu
Zheng
Z
Davidson
Anne
A
D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000235:genetics; D009838:Oligodeoxyribonucleotides / Q000138:chemical synthesis* / Q000494:pharmacology / Q000627:therapeutic use*; D051193:Toll-Like Receptors / Q000037:antagonists & inhibitors / Q000502:physiology
D009838:Oligodeoxyribonucleotides; D051193:Toll-Like Receptors